- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Telomir Pharmaceuticals beschließt neues Vergütungspaket für CEO | 2 | Investing.com Deutsch | ||
| 18.12. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development | 240 | ACCESS Newswire | No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir... ► Artikel lesen | |
| 17.12. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 26.11. | RECIPHARM AB: Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support | 1 | Cision News | ||
| 25.11. | Telomir reports PSA reduction in prostate cancer cells with lead drug | 2 | Investing.com | ||
| 25.11. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells | 259 | ACCESS Newswire | PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November... ► Artikel lesen | |
| 21.11. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells | 327 | ACCESS Newswire | Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL... ► Artikel lesen | |
| 20.11. | Craig Eagle verlässt Aufsichtsrat von Telomir Pharmaceuticals | 1 | Investing.com Deutsch | ||
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 20.11. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine in Reducing Intracellular Iron in a Human Cell Line | 340 | ACCESS Newswire | New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating... ► Artikel lesen | |
| 12.11. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11. | Telomir Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 23.10. | Telomir-1 shows promise in modulating cancer defense genes | 13 | Investing.com | ||
| 23.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's "Kill-and-Clean" Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo | 277 | ACCESS Newswire | New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ACCESS... ► Artikel lesen | |
| 22.10. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10. | Telomir to Buy TELI | 2 | Baystreet.ca | ||
| 21.10. | Telomir Pharmaceuticals executes LOI for worldwide rights to Telomir-1 | 3 | Seeking Alpha | ||
| 21.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth | 299 | ACCESS Newswire | Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for partnerships, licensing, and long-term value creation.... ► Artikel lesen | |
| 14.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer | 215 | ACCESS Newswire | Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways. MIAMI... ► Artikel lesen | |
| 14.10. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings |
1 2 3 4 Weiter >>
73 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | +3,14 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| MODERNA | 27,580 | -9,19 % | Nvidia Rises, Moderna and Brown-Forman Slump, and More | ||
| VALNEVA | 3,654 | -1,77 % | Samstags-Check: Valneva-Aktie sorgt für Gesprächsstoff - wie geht es Montag weiter? | ||
| INOVIO PHARMACEUTICALS | 1,880 | -3,59 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,259 | -0,12 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,810 | +3,37 % | Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) | ||
| BAVARIAN NORDIC | 25,010 | -0,08 % | Bavarian Nordic A/S: Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees | COPENHAGEN, Denmark, December 18, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management... ► Artikel lesen | |
| GERON | 1,141 | +1,33 % | Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation | Restructuring Supports RYTELO- U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| IMMUNITYBIO | 1,764 | -8,17 % | ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe | ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,334 | +9,22 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| ZAI LAB LTD ADR | 14,600 | -2,67 % | Zai Lab Receives Approval In China For Schizophrenia Drug COBENFY | ||
| VERASTEM | 6,400 | 0,00 % | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 21,005 | +2,41 % | Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results | Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,280 | -1,33 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ANNOVIS BIO | 3,265 | +7,58 % | Annovis Bio Inc.: Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,045 (+3,18 %) liegt der Kurs bei 1,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.